INKT
Mink Therapeutics Inc
NASDAQ: INKT · HEALTHCARE · BIOTECHNOLOGY
$11.81
+8.55% today
Updated 2026-04-29
Market cap
$55.32M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-2.93
Dividend yield
—
52W range
$6 – $76
Volume
0.4M
Mink Therapeutics Inc (INKT) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $689626.00 | $0.00 | $0.00 | $2.70B | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | -100.0% | — | — | -100.0% | — | — |
| Cost of revenue | — | $55060.00 | $77960.00 | $121749.00 | $204617.00 | $215437.00 | $181745.00 |
| Gross profit | $689626.00 | $-55060.00 | $-77960.00 | $-121749.00 | $-204617.00 | $-215437.00 | $-181745.00 |
| Gross margin | 100.0% | — | — | -0.0% | — | — | — |
| R&D | $19.65M | $9.51M | $13.97M | $23.12M | $15.49M | $6.34M | $5.76B |
| SG&A | $3.83M | $1.29M | $4.64M | $7.83M | $7.43M | $4.31B | $6.73B |
| Operating income | $-22.28M | $-10.80M | $-18.61M | $-30.95M | $-22.92M | $-10.65M | $-12.49M |
| Operating margin | -3231.4% | — | — | -1.1% | — | — | — |
| EBITDA | $-22.20M | $-13.74M | $-27.70M | $-27.87M | $-22.25M | $-10.57M | $-12.31M |
| EBITDA margin | -3219.8% | — | — | -1.0% | — | — | — |
| EBIT | $-22.24M | $-13.80M | $-27.78M | $-27.99M | $-22.46M | $-10.78M | $-12.49M |
| Interest expense | $1.56M | $2.44M | $2.43M | $253323.00 | — | — | — |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-23.80M | $-16.24M | $-30.21M | $-27.99M | $-22.46M | $-10.78M | $-12.49M |
| Net income growth (YoY) | — | +31.8% | -86.1% | +7.4% | +19.8% | +52.0% | -15.9% |
| Profit margin | -3451.5% | — | — | -1.0% | — | — | — |